Bone Biologics Corp
BBLG
NASDAQ
Biotechnology
$0.66
USD
-0.02 (-2.86%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.19M
Volume 164.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-2.86M
TTM
+33.0%
YoY
Operating Cash Flow
$-2.57M
TTM
+31.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 0.6 | 0.6 | 0.5 | 0.5 | 0.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 1.0 | 0.7 | 0.7 | 0.7 | 0.8 |
Operating Income | -1.0 | -0.7 | -0.7 | -0.7 | -0.8 |
EBITDA | -1.0 | -0.7 | -0.7 | -0.7 | -0.8 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Income Before Income Taxes | -1.0 | -0.7 | -0.7 | -0.7 | -0.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -1.0 | -0.7 | -0.7 | -0.7 | -0.8 |
Consolidated Net Income / Loss | -1.0 | -0.7 | -0.7 | -0.7 | -0.8 |
Net Income Attributable to Common Shareholders | -1.0 | -0.7 | -0.7 | -0.7 | -0.8 |
Basic EPS | -$1.92 | -$1.33 | -$0.37 | -$0.38 | -$0.43 |
Diluted EPS | -$1.92 | -$1.33 | -$0.37 | -$0.38 | -$0.43 |
Basic Shares Outstanding | 0.5M | 0.6M | 1.8M | 1.8M | 1.8M |
Diluted Shares Outstanding | 0.5M | 0.6M | 1.8M | 1.8M | 1.8M |